Indoco Remedies gets EIR for Goa manufacturing facility from USFDA

18 Jan 2024 Evaluate

Indoco Remedies has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the Pre-Approval Inspection (PAI) conducted for the oral dosage form at the manufacturing facility located at Goa Plant-I, L-14 Verna Industrial Area Verna, Goa, India, in October 2023. The Company had addressed the observations comprehensively and within the stipulated time. The receipt of the Establishment Inspection Report indicates a successful closure of the inspection. The PAI was conducted for two drug product applications (ANDAs) filed from this facility, for which approvals are expected soon.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

325.50 -3.05 (-0.93%)
29-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.